Single User
£3750
PDF
36 pages

Dry Eye Syndrome Forecast in 7 Major Markets 2015-2025


Dry Eye Syndrome is a disorder of the tear film which is caused by Aqueous Tear Deficiency (ATD) (insufficient tear production) or by Meibomian Gland Dysfunction (MGD) (excessive tear evaporation), or in some cases patients have both conditions. Inflammation of the ocular surface and the lachrymal glands are observed in patients. This report provides the current prevalent population for Dry Eye Syndrome across 7 Major Markets (USA, France, Germany, Italy, Spain, UK and Japan) split by gender and 5-year age cohort. Along with the current prevalence, the report provides an overview of the types, occlusion locations and the prevalence of associated disorders of Dry Eye Syndrome. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Dry Eye Syndrome have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Dry Eye Syndrome include:

  • Glaucoma
  • Diabetes
  • Hypertension
  • Rheumatoid Arthritis
  • Sjorgen’s Syndrome
  • Dry Mouth

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Able to quantify patient populations in global Dry Eye Syndrome’s market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of Dry Eye Syndrome and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on Dry Eye Syndrome’s prevalent population.
  • Identify sub-populations within Dry Eye Syndrome which require treatment.
  • Gain an understanding of the specific markets that have the largest number of Dry Eye Syndrome patients.
Table of Contents
  • List of Tables and Figures
  • Introduction
  • Cause of the Disease
  • Risk Factors & Prevention
  • Diagnosis of the Disease
  • Variation by Geography/Ethnicity
  • Disease Prognosis &Clinical Course
  • Key Co-morbid Conditions/ Features Associated with the Disease
  • Methodology for Quantification of Patient Numbers
  • Top-Line Prevalence for Dry Eye Syndrome
  • Main Complications and Features of Dry Eye Syndrome
    • Type of Dry Eye Syndrome in Patients
    • The Presence of Sjorgens Syndrome in Dry Eye Syndrome Patients with ATD
    • Severity of MGD in Dry Eye Syndrome Patients
    • The Type of Sjorgens Syndrome Present in Dry Eye Syndrome Patients
    • Common Diagnostic Test Results of Dry Eye Syndrome Patients
    • Prevalence of Co-morbidities in Dry Eye Syndrome Patients
  • Abbreviations used in the Report
  • Other Black Swan Analysis Publications
  • Black Swan Analysis Online Patient-Based Databases
  • Patient-Based Offering
  • Online Pricing Data and Platforms
  • References
  • Appendix
List of Tables & Figures
  • Prevalence of Dry Eye Syndrome, total (000s)
  • Prevalence of Dry Eye Syndrome, males (000s)
  • Prevalence of Dry Eye Syndrome, females (000s)
  • Dry Eye Syndrome by Type, total (000s)
  • Prevalence of ATD Type Dry Eye Syndrome Patients with or without Sjorgens Syndrome, total (000s)
  • Severity of MGD in Dry Eye Syndrome patients, total (000s)
  • Type of SS Present in Dry Eye Patients Suffering from SS, total (000s)
  • Severity of Corneal Staining, total (000s)
  • Tear Production of Dry Eye Syndrome Patients, total (000s)
  • TBUT of Dry Eye Syndrome Patients, total (000s)
  • Prevalence of Glaucoma in Dry Eye Syndrome patients, total (000s)
  • Prevalence of Diabetes in Dry Eye Syndrome patients, total (000s)
  • Prevalence of Hypertension in Dry Eye Syndrome patients, total (000s)
  • Prevalence of Rheumatoid Arthritis in Dry Eye Syndrome patients, total (000s)
  • Prevalence of Dry Mouth Symptoms in Dry Eye Syndrome patients, total (000s)
  • Abbreviations and Acronyms used in the Report
  • USA Prevalence of Dry Eye Syndrome by 5-yr age cohort, males (000s)
  • USA Prevalence of Dry Eye Syndrome by 5-yr age cohort, females (000s)
  • France Prevalence of Dry Eye Syndrome by 5-yr age cohort, males (000s)
  • France Prevalence of Dry Eye Syndrome by 5-yr age cohort, females (000s)
  • Germany Prevalence of Dry Eye Syndrome by 5-yr age cohort, males (000s)
  • Germany Prevalence of Dry Eye Syndrome by 5-yr age cohort, females (000s)
  • Italy Prevalence of Dry Eye Syndrome by 5-yr age cohort, males (000s)
  • Italy Prevalence of Dry Eye Syndrome by 5-yr age cohort, females (000s)
  • Spain Prevalence of Dry Eye Syndrome by 5-yr age cohort, males (000s)
  • Spain Prevalence of Dry Eye Syndrome by 5-yr age cohort, females (000s)
  • United Kingdom Prevalence of Dry Eye Syndrome by 5-yr age cohort, males (000s)
  • United Kingdom Prevalence of Dry Eye Syndrome by 5-yr age cohort, females (000s)
  • Japan Prevalence of Dry Eye Syndrome by 5-yr age cohort, males (000s)
  • Japan Prevalence of Dry Eye Syndrome by 5-yr age cohort, females (000s)
France, Germany, Italy, Japan, Spain, United Kingdom, United States of America